Dublin, May 14, 2025 (GLOBE NEWSWIRE) -- The "Antibody Conjugate Oligonucleotide Market - A Global and Regional Analysis: Focus on Type, Oligonucleotide Type, Target Disease, and Country Analysis ...

Avidity Biosciences, Inc. (NASDAQ:RNA) is a leader in the antibody oligonucleotide conjugate ("AOC") space. The stock has done very well in the last 12 months since I covered it, going up 3x.

Fujifilm Validates Cancer Cell-Targeting Potential of Peptide Oligonucleotide Conjugates with Novel Cyclic Peptides. Research highlights to be presented at TIDES USA 2025.

Avidity Biosciences, Inc.'s stock surged ~650% in the past year, driven by positive developments in its Antibody Oligonucleotide Conjugates (AOCs) for muscular disorders. Key catalysts include a ...

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design ...

In the assessment of 12-month price targets, analysts unveil insights for Avidity Biosciences, presenting an average target ...

More information: David P. Chimento et al, Bioanalytical Assays for Oligonucleotide Therapeutics: Adding Antibody-Based ...

AOC 1020 is designed to reduce the expression of DUX4 mRNA and DUX4 protein in muscles. The Food and Drug Administration (FDA) has granted Fast Track designation to AOC 1020 for the treatment of ...

The global antibody conjugate oligonucleotide market is on track for significant growth, driven by increased demand for targeted therapies in oncology, autoimmune diseases, and genetic disorders, ...

The global antibody conjugate oligonucleotide market is on track for significant growth, driven by increased demand for targeted therapies in oncology, autoimmune diseases, and genetic disorders, ...